董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jay R. Venkatesan | 男 | Director | 48 | 5.93万美元 | 未持股 | 2020-04-20 |
| Paul Sekhri | 男 | Independent Director | 61 | 7.26万美元 | 未持股 | 2020-04-20 |
| Robert Conway | 男 | Independent Director | 66 | 7.80万美元 | 未持股 | 2020-04-20 |
| James Topper | 男 | Independent Director | 58 | 6.93万美元 | 未持股 | 2020-04-20 |
| Xiangmin Cui | 男 | Independent Director | 51 | 未披露 | 未持股 | 2020-04-20 |
| Mitchell H. Gold | 男 | Director, Executive Chairman and Chief Executive Officer | 53 | 155.59万美元 | 未持股 | 2020-04-20 |
| Peter Thompson | 男 | Independent Director | 60 | 7.18万美元 | 未持股 | 2020-04-20 |
| Christopher Peetz | 男 | Independent Director | 41 | 6.68万美元 | 未持股 | 2020-04-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stanford Peng | 男 | President and Head of Research and Development | 49 | 97.06万美元 | 未持股 | 2020-04-20 |
| Mitchell H. Gold | 男 | Director, Executive Chairman and Chief Executive Officer | 53 | 155.59万美元 | 未持股 | 2020-04-20 |
| Paul Rickey | 男 | Senior Vice President, Chief Financial Officer and Corporate Secretary | 41 | 80.95万美元 | 未持股 | 2020-04-20 |
董事简历
中英对照 | 中文 | 英文- Jay R. Venkatesan
-
Jay R. Venkatesan自2017年7月Nivalis和Private Alpine完成合并以来，一直担任Alpine Immune Sciences, Inc.的董事会成员，担任Alpine Immune科学公司，Inc.于2017年7月至2018年8月担任总裁，此前曾于2015年11月至2016年6月担任Private Alpine的首席执行官，并于2016年6月至2017年7月担任Private Alpine的总裁。自2015年11月以来，Venkatesan博士还担任Private Alpine的董事会成员。自2018年5月以来，Venkatesan博士一直担任私营制药公司Angion Biomedica公司的首席执行官和董事会成员。在加入Private Alpine之前，Venkatesan博士是Oncothyreon，Inc.（现为Cascadian治疗）的执行副总裁兼总经理，在Oncothyreon收购Alpine Biosciences后，该公司于2018年3月被Seattle Genetics，Inc.收购，2014年8月至2015年5月，他曾担任联合创始人兼首席执行官。此前，Venkatesan博士曾于2008年至2013年担任全球医疗保健股票基金Ayer Capital Management的创始人、投资组合经理和董事总经理。在此之前，他于2002年至2007年担任Brookside Capital Partners的董事。在他职业生涯的早期，Venkatesan博士于1995年至1996年在Partricof & Co. Ventures从事医疗保健投资，并于1993年至1995年在麦肯锡公司从事咨询工作。Venkatesan博士目前是Alpine Bioventures的管理合伙人。此外，Venkatesan博士目前在CellBiotherapy和Exicure治疗（纳斯达克股票代码：XCUR）的董事会任职。Venkatesan博士获得了宾夕法尼亚大学医学院的医学博士学位、宾夕法尼亚大学沃顿商学院的工商管理硕士学位和文学学士学位。威廉姆斯学院化学博士。
Jay R. Venkatesan,has served as a member of Elicio's Board of Directors since June 2023 and previously served as Chairman of Angion's Board of Directors from January 2022 until the Merger. From May 2018 to June 2023, Dr. Venkatesan served as Angion's President and Chief Executive Officer. Dr. Venkatesan has served as a Managing Partner of Alpine BioVentures, an investment firm since July 2015. From July 2015 to August 2018, Dr. Venkatesan was Co-Founder and President of Alpine Immune Sciences, Inc., an immunotherapy company, and also served as its Chief Executive Officer from July 2015 to June 2016. Additionally, as Managing Partner of Alpine BioVentures, from January 2014 to August 2014, Dr. Venkatesan served as Founder and Chief Executive Officer of Alpine BioSciences, Inc., a biotechnology company, which was acquired by Cascadian Therapeutics, Inc. From January 2008 to July 2015, Dr. Venkatesan served as the Founder and Managing Member of Ayer Capital, a global healthcare investment fund. Prior to that, Dr. Venkatesan served for six years as a director at Brookside Capital, the hedge fund subsidiary of Bain Capital, where he co-managed healthcare investments. Dr. Venkatesan was also a consultant at McKinsey & Company, a consulting firm, and a venture investor with Apax Partners, an investment firm. Since 2018, Dr. Venkatesan has served on the board of Zylem Biosciences, Inc., a private biotechnology company. Dr. Venkatesan previously served on the board of Alpine Immune Sciences, Inc. (acquired by Vertex Pharmaceuticals Incorporated) from June 2015 to July 2022, Iovance Biotherapeutics Inc. from 2013 to 2018, and Cell Biotherapies, Inc. from 2015 until its acquisition by Vaxanix Bio, Ltd. in 2023. Dr. Venkatesan has an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from The Wharton School of the University of Pennsylvania, and a B.A. from Williams College. - Jay R. Venkatesan自2017年7月Nivalis和Private Alpine完成合并以来，一直担任Alpine Immune Sciences, Inc.的董事会成员，担任Alpine Immune科学公司，Inc.于2017年7月至2018年8月担任总裁，此前曾于2015年11月至2016年6月担任Private Alpine的首席执行官，并于2016年6月至2017年7月担任Private Alpine的总裁。自2015年11月以来，Venkatesan博士还担任Private Alpine的董事会成员。自2018年5月以来，Venkatesan博士一直担任私营制药公司Angion Biomedica公司的首席执行官和董事会成员。在加入Private Alpine之前，Venkatesan博士是Oncothyreon，Inc.（现为Cascadian治疗）的执行副总裁兼总经理，在Oncothyreon收购Alpine Biosciences后，该公司于2018年3月被Seattle Genetics，Inc.收购，2014年8月至2015年5月，他曾担任联合创始人兼首席执行官。此前，Venkatesan博士曾于2008年至2013年担任全球医疗保健股票基金Ayer Capital Management的创始人、投资组合经理和董事总经理。在此之前，他于2002年至2007年担任Brookside Capital Partners的董事。在他职业生涯的早期，Venkatesan博士于1995年至1996年在Partricof & Co. Ventures从事医疗保健投资，并于1993年至1995年在麦肯锡公司从事咨询工作。Venkatesan博士目前是Alpine Bioventures的管理合伙人。此外，Venkatesan博士目前在CellBiotherapy和Exicure治疗（纳斯达克股票代码：XCUR）的董事会任职。Venkatesan博士获得了宾夕法尼亚大学医学院的医学博士学位、宾夕法尼亚大学沃顿商学院的工商管理硕士学位和文学学士学位。威廉姆斯学院化学博士。
- Jay R. Venkatesan,has served as a member of Elicio's Board of Directors since June 2023 and previously served as Chairman of Angion's Board of Directors from January 2022 until the Merger. From May 2018 to June 2023, Dr. Venkatesan served as Angion's President and Chief Executive Officer. Dr. Venkatesan has served as a Managing Partner of Alpine BioVentures, an investment firm since July 2015. From July 2015 to August 2018, Dr. Venkatesan was Co-Founder and President of Alpine Immune Sciences, Inc., an immunotherapy company, and also served as its Chief Executive Officer from July 2015 to June 2016. Additionally, as Managing Partner of Alpine BioVentures, from January 2014 to August 2014, Dr. Venkatesan served as Founder and Chief Executive Officer of Alpine BioSciences, Inc., a biotechnology company, which was acquired by Cascadian Therapeutics, Inc. From January 2008 to July 2015, Dr. Venkatesan served as the Founder and Managing Member of Ayer Capital, a global healthcare investment fund. Prior to that, Dr. Venkatesan served for six years as a director at Brookside Capital, the hedge fund subsidiary of Bain Capital, where he co-managed healthcare investments. Dr. Venkatesan was also a consultant at McKinsey & Company, a consulting firm, and a venture investor with Apax Partners, an investment firm. Since 2018, Dr. Venkatesan has served on the board of Zylem Biosciences, Inc., a private biotechnology company. Dr. Venkatesan previously served on the board of Alpine Immune Sciences, Inc. (acquired by Vertex Pharmaceuticals Incorporated) from June 2015 to July 2022, Iovance Biotherapeutics Inc. from 2013 to 2018, and Cell Biotherapies, Inc. from 2015 until its acquisition by Vaxanix Bio, Ltd. in 2023. Dr. Venkatesan has an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from The Wharton School of the University of Pennsylvania, and a B.A. from Williams College.
- Paul Sekhri
-
Paul Sekhri，2019-2022：专注于移植的生物技术公司egenesis, Inc.的总裁兼首席执行官。2015-2019年：glycerol公司（专注于自身免疫性疾病的生物制药公司）总裁兼首席执行官。2016-2017年：运营合伙人，Highline Therapeutics，一家由Versant ventures推出的生物技术孵化器。2014-2015年：跨国制药公司赛诺菲（Sanofi s.a.）的高级副总裁，综合医疗。2013-2014年：全球制药公司Teva Pharmaceutical Industries, Ltd.集团执行副总裁，全球业务发展和首席战略官。2009-2013年：全球私人投资公司TPG capital旗下TPG Biotech的运营合伙人和生物技术运营集团负责人。2004-2009年：Cerimon Pharmaceuticals, Inc.（一家制药公司）的总裁兼首席执行官。Spring Discovery, Inc.， 2021-至今。Longboard Pharmaceuticals（2020年至今）（公众）。egenesis, Inc 。（2019年至今）。Ipsen S.A.（2018-至今）（公共）。Compugen Ltd.（2017-至今）（大众）。Pharming Group N.V。（2015年至今）（上市）。BiomX, Inc.（2020-2022）（大众）。Alpine Immune Sciences, Inc.（2017-2020）（公共）。马里兰大学动物学理学学士。马里兰大学医学院临床解剖学和神经科学研究生学习。
Paul Sekhri,currently serves as President and CEO of vTv Therapeutics Inc. (2022–present). Previously, he held CEO roles at eGenesis, Inc. (2019–2022), Lycera Corp. (2015–2019), and Cerimon Pharmaceuticals (2004–2009). His executive experience includes SVP of Integrated Care at Sanofi (2014–2015), Group EVP at Teva Pharmaceutical (2013–2014), and Operating Partner roles at TPG Biotech (2003–2013) and Hightine Therapeutics (2016–2017). He serves/has served on multiple public company boards including Compugen Ltd. (2017–present), Longboard Pharmaceuticals (2020–2024), and Ipsen S.A. (2018–2023). Sekhri holds a BS in Zoology from the University of Maryland and completed post-graduate studies in clinical anatomy and neuroscience at UMD School of Medicine. - Paul Sekhri，2019-2022：专注于移植的生物技术公司egenesis, Inc.的总裁兼首席执行官。2015-2019年：glycerol公司（专注于自身免疫性疾病的生物制药公司）总裁兼首席执行官。2016-2017年：运营合伙人，Highline Therapeutics，一家由Versant ventures推出的生物技术孵化器。2014-2015年：跨国制药公司赛诺菲（Sanofi s.a.）的高级副总裁，综合医疗。2013-2014年：全球制药公司Teva Pharmaceutical Industries, Ltd.集团执行副总裁，全球业务发展和首席战略官。2009-2013年：全球私人投资公司TPG capital旗下TPG Biotech的运营合伙人和生物技术运营集团负责人。2004-2009年：Cerimon Pharmaceuticals, Inc.（一家制药公司）的总裁兼首席执行官。Spring Discovery, Inc.， 2021-至今。Longboard Pharmaceuticals（2020年至今）（公众）。egenesis, Inc 。（2019年至今）。Ipsen S.A.（2018-至今）（公共）。Compugen Ltd.（2017-至今）（大众）。Pharming Group N.V。（2015年至今）（上市）。BiomX, Inc.（2020-2022）（大众）。Alpine Immune Sciences, Inc.（2017-2020）（公共）。马里兰大学动物学理学学士。马里兰大学医学院临床解剖学和神经科学研究生学习。
- Paul Sekhri,currently serves as President and CEO of vTv Therapeutics Inc. (2022–present). Previously, he held CEO roles at eGenesis, Inc. (2019–2022), Lycera Corp. (2015–2019), and Cerimon Pharmaceuticals (2004–2009). His executive experience includes SVP of Integrated Care at Sanofi (2014–2015), Group EVP at Teva Pharmaceutical (2013–2014), and Operating Partner roles at TPG Biotech (2003–2013) and Hightine Therapeutics (2016–2017). He serves/has served on multiple public company boards including Compugen Ltd. (2017–present), Longboard Pharmaceuticals (2020–2024), and Ipsen S.A. (2018–2023). Sekhri holds a BS in Zoology from the University of Maryland and completed post-graduate studies in clinical anatomy and neuroscience at UMD School of Medicine.
- Robert Conway
-
Robert Conway自2017年7月Nivalis和Private Alpine完成合并以来，一直担任Alpine Immune Sciences, Inc.的董事会成员，此前自2015年4月起担任Nivalis的董事会成员。从1999年到2012年，康威先生担任Array生物制药纳斯达克上市生物制药公司ARRY的首席执行官和董事会成员。在加入Array之前，Conway先生于1996年至1999年担任Hill Top Research的首席运营官兼执行副总裁。从1979年到1996年，康威先生在康宁公司（纽约证券交易所代码：GLW）担任过多个管理职位，包括合同研究机构康宁黑兹尔顿的公司副总裁和总经理。自2013年以来，康威先生一直担任方舟生物医药（纳斯达克股票代码：ABIO），一家上市生物制药公司的董事会，并于2014年6月被选为董事长。从2004年到2013年，康威先生在PRA国际（纳斯达克股票代码：PRAH）的董事会任职，该公司是一家上市公司，在他的部分任期内。Conway先生还是私营临床技术公司Signant Health和Advarra，Inc.的董事会成员。此外，康威先生还是Genstar Capital战略咨询委员会的成员。康威先生获得了学士学位。1976年获得马凯特大学会计学博士学位。
Robert Conway has served as a member of Alpine Immune Sciences, Inc.'s board of directors since the completion of the merger of Nivalis and Private Alpine in July 2017 and previously served as a member of the board of directors of Nivalis since April 2015. From 1999 to 2012 Mr. Conway served as the chief executive officer and member of the board of directors of Array BioPharma Nasdaq: ARRY, a publicly traded biopharmaceutical company. Prior to joining Array, Mr. Conway was the chief operating officer and executive vice president of Hill Top Research, from 1996 to 1999. From 1979 until 1996 Mr. Conway held various executive positions for Corning Inc. (NYSE: GLW), including corporate vice president and general manager of Corning Hazleton, a contract research organization. Since 2013 Mr. Conway has served on the board of directors of ARCA BioPharma (Nasdaq: ABIO), a publicly traded biopharmaceutical company, and was elected Chairman in June 2014. From 2004 to 2013 Mr. Conway served on the board of directors of PRA International (Nasdaq: PRAH), which was a public company for a portion of his tenure there. Mr. Conway is also a member of the board of directors of Signant Health and Advarra, Inc., private clinical technology companies. In addition, Mr. Conway is a member of the strategic advisory committee of Genstar Capital. Mr. Conway received a B.S. in accounting from Marquette University in 1976. - Robert Conway自2017年7月Nivalis和Private Alpine完成合并以来，一直担任Alpine Immune Sciences, Inc.的董事会成员，此前自2015年4月起担任Nivalis的董事会成员。从1999年到2012年，康威先生担任Array生物制药纳斯达克上市生物制药公司ARRY的首席执行官和董事会成员。在加入Array之前，Conway先生于1996年至1999年担任Hill Top Research的首席运营官兼执行副总裁。从1979年到1996年，康威先生在康宁公司（纽约证券交易所代码：GLW）担任过多个管理职位，包括合同研究机构康宁黑兹尔顿的公司副总裁和总经理。自2013年以来，康威先生一直担任方舟生物医药（纳斯达克股票代码：ABIO），一家上市生物制药公司的董事会，并于2014年6月被选为董事长。从2004年到2013年，康威先生在PRA国际（纳斯达克股票代码：PRAH）的董事会任职，该公司是一家上市公司，在他的部分任期内。Conway先生还是私营临床技术公司Signant Health和Advarra，Inc.的董事会成员。此外，康威先生还是Genstar Capital战略咨询委员会的成员。康威先生获得了学士学位。1976年获得马凯特大学会计学博士学位。
- Robert Conway has served as a member of Alpine Immune Sciences, Inc.'s board of directors since the completion of the merger of Nivalis and Private Alpine in July 2017 and previously served as a member of the board of directors of Nivalis since April 2015. From 1999 to 2012 Mr. Conway served as the chief executive officer and member of the board of directors of Array BioPharma Nasdaq: ARRY, a publicly traded biopharmaceutical company. Prior to joining Array, Mr. Conway was the chief operating officer and executive vice president of Hill Top Research, from 1996 to 1999. From 1979 until 1996 Mr. Conway held various executive positions for Corning Inc. (NYSE: GLW), including corporate vice president and general manager of Corning Hazleton, a contract research organization. Since 2013 Mr. Conway has served on the board of directors of ARCA BioPharma (Nasdaq: ABIO), a publicly traded biopharmaceutical company, and was elected Chairman in June 2014. From 2004 to 2013 Mr. Conway served on the board of directors of PRA International (Nasdaq: PRAH), which was a public company for a portion of his tenure there. Mr. Conway is also a member of the board of directors of Signant Health and Advarra, Inc., private clinical technology companies. In addition, Mr. Conway is a member of the strategic advisory committee of Genstar Capital. Mr. Conway received a B.S. in accounting from Marquette University in 1976.
- James Topper
-
James Topper，硕士，博士，自2014年4月起担任董事会成员。他自2005年起担任Frazier Healthcare Ventures（一个风险资本公司）的一般合伙人。在加入Frazier Healthcare Ventures之前，他担任Millennium Pharmaceuticals股份有限公司（Millennium Pharmaceuticals, Inc）心血管研究与发展部负责人，也是COR Therapeutics股份有限公司（COR Therapeutics, Inc）生物副总裁，后来公司被Millennium Pharmaceuticals收购。他目前在Amicus Therapeutics股份有限公司（Amicus Therapeutics, Inc）和几家私人拥有的生物技术公司董事会工作，他先前在La Jolla Pharmaceuticals公司（La Jolla Pharmaceuticals Company）和Portola Pharmaceuticals股份有限公司（Portola Pharmaceuticals, Inc）董事会工作。他拥有迈阿密大学（University of Michigan）学士学位和斯坦福大学医学院（Stanford University School of Medicine）硕士和博士学位。
James Topper,has also served as the Managing General Partner at Frazier, a venture capital firm, with whom he served as a Partner from 2003 to 2005. Prior to that, from 2002 to 2003, Dr. Topper served as head of the Cardiovascular Research and Development Division at Millennium Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Topper has served as a member of the board of directors of the publicly traded company NewAmsterdam Pharma B.V., a biotechnology company, since November 2022. Dr. Topper previously served as a member of the board of directors of the following publicly traded companies: Alpine lmmune Sciences, Inc., a biotechnology company, from June 2016 to May 2024 and AnaptsyBio, Inc., a biotechnology company, from November 2007 to September 2023. Dr. Topper received a B.S. in Biology from the University of Michigan and an M.D. and a Ph.D. in Biophysics from the Stanford University School of Medicine. He did his postgraduate training in internal medicine and cardiovascular disease at the Brigham and Women's Hospital in Boston and was board certified in both disciplines. - James Topper，硕士，博士，自2014年4月起担任董事会成员。他自2005年起担任Frazier Healthcare Ventures（一个风险资本公司）的一般合伙人。在加入Frazier Healthcare Ventures之前，他担任Millennium Pharmaceuticals股份有限公司（Millennium Pharmaceuticals, Inc）心血管研究与发展部负责人，也是COR Therapeutics股份有限公司（COR Therapeutics, Inc）生物副总裁，后来公司被Millennium Pharmaceuticals收购。他目前在Amicus Therapeutics股份有限公司（Amicus Therapeutics, Inc）和几家私人拥有的生物技术公司董事会工作，他先前在La Jolla Pharmaceuticals公司（La Jolla Pharmaceuticals Company）和Portola Pharmaceuticals股份有限公司（Portola Pharmaceuticals, Inc）董事会工作。他拥有迈阿密大学（University of Michigan）学士学位和斯坦福大学医学院（Stanford University School of Medicine）硕士和博士学位。
- James Topper,has also served as the Managing General Partner at Frazier, a venture capital firm, with whom he served as a Partner from 2003 to 2005. Prior to that, from 2002 to 2003, Dr. Topper served as head of the Cardiovascular Research and Development Division at Millennium Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Topper has served as a member of the board of directors of the publicly traded company NewAmsterdam Pharma B.V., a biotechnology company, since November 2022. Dr. Topper previously served as a member of the board of directors of the following publicly traded companies: Alpine lmmune Sciences, Inc., a biotechnology company, from June 2016 to May 2024 and AnaptsyBio, Inc., a biotechnology company, from November 2007 to September 2023. Dr. Topper received a B.S. in Biology from the University of Michigan and an M.D. and a Ph.D. in Biophysics from the Stanford University School of Medicine. He did his postgraduate training in internal medicine and cardiovascular disease at the Brigham and Women's Hospital in Boston and was board certified in both disciplines.
- Xiangmin Cui
-
Xiangmin Cui，2010年2月以来，一直担任本公司董事。他现为的高级助理，这是一个风投公司，管理着投资于各种医疗保健领域的近16亿美元资金。2006年加入该公司之前，他担任Southern Research Institute的战略投资规划总监，该机构研究开发了6种抗癌药物，已被U.S. Food and Drug Administratio批准。此前，他曾参与创办美国生物技术公司Pan Pacific Pharmaceuticals，和中国制药公司Hucon Biopharmaceuticals。1998-2002，他担任Pan Pacific Pharmaceuticals 的首席科学官、执行副总裁；2003-2005，担任Hucon Biopharmaceuticals的首席执行官、总裁；担任上述职务时，他领导了肿瘤、传染病、炎症领域的一些重要技术的评估和收购工作。他还曾参与创办CNetwork，这是位于旧金山的非营利组织，服务于北美的中国社团。他在Stanford University获得癌症生物博士学位，在北京大学获得分子生物学士学位。
Xiangmin Cui has served as a member of our board of directors since January 2019. Dr. Cui has served as managing director of Decheng Capital, an investment firm focused on life sciences companies, since he founded the firm in 2011. Prior to founding Decheng, Dr. Cui was an investment partner at Bay City Capital, an international life science venture capital firm in San Francisco. Dr. Cui was previously director of strategic investment for the Southern Research Institute, a not-for-profit research organization. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals, where he led efforts in discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases. Dr. Cui has served as a member of the board of directors of ARMO BioSciences, Inc., a publicly-traded immuno-oncology company acquired by Eli Lilly and Company in May 2018 from August 2017 to May 2018 and also currently serves on the boards of directors of several private companies. Dr. Cui holds a Ph.D. in Cancer Biology from Stanford University and a BS and MS in Molecular Biology from Peking University. - Xiangmin Cui，2010年2月以来，一直担任本公司董事。他现为的高级助理，这是一个风投公司，管理着投资于各种医疗保健领域的近16亿美元资金。2006年加入该公司之前，他担任Southern Research Institute的战略投资规划总监，该机构研究开发了6种抗癌药物，已被U.S. Food and Drug Administratio批准。此前，他曾参与创办美国生物技术公司Pan Pacific Pharmaceuticals，和中国制药公司Hucon Biopharmaceuticals。1998-2002，他担任Pan Pacific Pharmaceuticals 的首席科学官、执行副总裁；2003-2005，担任Hucon Biopharmaceuticals的首席执行官、总裁；担任上述职务时，他领导了肿瘤、传染病、炎症领域的一些重要技术的评估和收购工作。他还曾参与创办CNetwork，这是位于旧金山的非营利组织，服务于北美的中国社团。他在Stanford University获得癌症生物博士学位，在北京大学获得分子生物学士学位。
- Xiangmin Cui has served as a member of our board of directors since January 2019. Dr. Cui has served as managing director of Decheng Capital, an investment firm focused on life sciences companies, since he founded the firm in 2011. Prior to founding Decheng, Dr. Cui was an investment partner at Bay City Capital, an international life science venture capital firm in San Francisco. Dr. Cui was previously director of strategic investment for the Southern Research Institute, a not-for-profit research organization. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals, where he led efforts in discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases. Dr. Cui has served as a member of the board of directors of ARMO BioSciences, Inc., a publicly-traded immuno-oncology company acquired by Eli Lilly and Company in May 2018 from August 2017 to May 2018 and also currently serves on the boards of directors of several private companies. Dr. Cui holds a Ph.D. in Cancer Biology from Stanford University and a BS and MS in Molecular Biology from Peking University.
- Mitchell H. Gold
-
自Nivalis Therapeutics，Inc.（我们称为Nivalis和Alpine Immune Sciences）合并完成以来，MitchellH.Gold一直担任我们的执行主席、首席执行官和董事会成员，Inc.（我们称为Private Alpine）于2017年7月合并之前，自2016年6月起担任Private Alpine的首席执行官，自2015年1月起担任Private Alpine的执行主席兼董事会成员。在共同创立Private Alpine之前，Gold博士于2012年至2014年担任Alpine Biosciences（一家私人持有的生物技术公司）的董事长兼创始人。从2001年到2012年，Gold博士在Dendreon Corporation（Valeant Pharmaceuticals International，Inc.通过资产购买协议收购）担任多个职位，包括总裁、首席执行官和董事会主席。在职业生涯早期，从2000年到2001年，Gold博士担任Data Critical的业务发展Vice President。从1995年到2000年，Gold博士担任Elixis Corporation的总裁兼首席执行官。Gold博士目前是Alpine BioVentures的管理合伙人。Gold博士持有Rush University Medical Center的Rush Medical College的医学博士学位，以及威斯康星大学（University of Wisconsin）的生物学学士学位。
Mitchell H. Gold has served as Alpine Immune Sciences, Inc.'s executive chairman, chief executive officer and a member of Alpine Immune Sciences, Inc.'s board of directors since the completion of the merger of Nivalis Therapeutics, Inc. which we refer to as Nivalis and Alpine Immune Sciences, Inc. (which we refer to as Private Alpine) in July 2017 and prior to the merger served as Private Alpine's chief executive officer since June 2016 and as Private Alpine's executive chairman and member of Private Alpine's board of directors since January 2015. Prior to co-founding Private Alpine, Dr. Gold was Chairman and Founder of Alpine Biosciences, a privately-held biotech company, from 2012 to 2014. From 2001 to 2012 Dr. Gold served in a variety of roles with Dendreon Corporation (which was acquired by Valeant Pharmaceuticals International, Inc. through an asset purchase agreement), including President, Chief Executive Officer, and Chairman of the board of directors. Earlier in his career, Dr. Gold served as Vice President of Business Development at Data Critical from 2000 to 2001. From 1995 to 2000 Dr. Gold was President and Chief Executive Officer of Elixis Corporation. Dr. Gold is currently a Managing Partner at Alpine BioVentures. Dr. Gold holds an M.D. from Rush Medical College of Rush University Medical Center and a B.S. in Biology from the University of Wisconsin. - 自Nivalis Therapeutics，Inc.（我们称为Nivalis和Alpine Immune Sciences）合并完成以来，MitchellH.Gold一直担任我们的执行主席、首席执行官和董事会成员，Inc.（我们称为Private Alpine）于2017年7月合并之前，自2016年6月起担任Private Alpine的首席执行官，自2015年1月起担任Private Alpine的执行主席兼董事会成员。在共同创立Private Alpine之前，Gold博士于2012年至2014年担任Alpine Biosciences（一家私人持有的生物技术公司）的董事长兼创始人。从2001年到2012年，Gold博士在Dendreon Corporation（Valeant Pharmaceuticals International，Inc.通过资产购买协议收购）担任多个职位，包括总裁、首席执行官和董事会主席。在职业生涯早期，从2000年到2001年，Gold博士担任Data Critical的业务发展Vice President。从1995年到2000年，Gold博士担任Elixis Corporation的总裁兼首席执行官。Gold博士目前是Alpine BioVentures的管理合伙人。Gold博士持有Rush University Medical Center的Rush Medical College的医学博士学位，以及威斯康星大学（University of Wisconsin）的生物学学士学位。
- Mitchell H. Gold has served as Alpine Immune Sciences, Inc.'s executive chairman, chief executive officer and a member of Alpine Immune Sciences, Inc.'s board of directors since the completion of the merger of Nivalis Therapeutics, Inc. which we refer to as Nivalis and Alpine Immune Sciences, Inc. (which we refer to as Private Alpine) in July 2017 and prior to the merger served as Private Alpine's chief executive officer since June 2016 and as Private Alpine's executive chairman and member of Private Alpine's board of directors since January 2015. Prior to co-founding Private Alpine, Dr. Gold was Chairman and Founder of Alpine Biosciences, a privately-held biotech company, from 2012 to 2014. From 2001 to 2012 Dr. Gold served in a variety of roles with Dendreon Corporation (which was acquired by Valeant Pharmaceuticals International, Inc. through an asset purchase agreement), including President, Chief Executive Officer, and Chairman of the board of directors. Earlier in his career, Dr. Gold served as Vice President of Business Development at Data Critical from 2000 to 2001. From 1995 to 2000 Dr. Gold was President and Chief Executive Officer of Elixis Corporation. Dr. Gold is currently a Managing Partner at Alpine BioVentures. Dr. Gold holds an M.D. from Rush Medical College of Rush University Medical Center and a B.S. in Biology from the University of Wisconsin.
- Peter Thompson
-
Peter Thompson，曾担任Corvus Pharmaceuticals， Inc.的成员。自2014年11月担任董事会成员，并共同创立了公司。Thompson博士是投资公司OrbiMed Advisors LLC的成员。Thompson博士目前担任ARS Pharmaceuticals， Inc.（原Silverback Therapeutics， Inc.）， Edgewise Therapeutics, Inc.和Sionna Therapeutics， Inc.以及几家私人公司的董事会成员。此前，Thompson博士担任Alpine Immune Sciences， Inc.、分贝治疗公司、Janux Therapeutics， Inc.、PMV Pharmaceuticals, Inc.和precpretherapeutics Inc.的董事会成员。Thompson博士此前还曾担任Trubion Pharmaceuticals， Inc.、Chiron Corporation和Becton， Dickinson and Company的执行领导职务。Thompson博士是华盛顿大学神经外科副教授。此外，Thompson博士拥有多项专利，是董事会认证的内科医生和肿瘤学家。他持有Brown大学的分子生物学和数学学士学位，以及Brown大学Medical School的医学博士学位。
Peter Thompson,is a Partner at OrbiMed Advisors LLC, an investment firm focused on the healthcare sector, where he previously served as a Venture Partner since joining in September 2010. Dr. Thompson is also the Chairman of Terremoto Biosciences, Inc., a biotechnology company developing targeted therapeutics, since August 2024, where he previously served as President and Chief Executive Officer from August 2021 to August 2024. Dr. Thompson previously served as Chief Executive Officer and President of two private companies: Glia Biotherapeutics, Inc., a biopharmaceutical company targeting glia-mediated pathways from July 2018 to July 2023 and Terremoto Therapeutics Holdings, LLC, a drug discovery and development company from August 2021 to December 2022. Dr. Thompson currently serves on the boards of directors of several public companies, including Sionna Therapeutics, Inc. (since February 2022), Corvus Pharmaceuticals, Inc. (since November 2014), and ARS Pharmaceuticals Inc. (since April 2016). Dr. Thompson has previously served on the boards of directors of Alpine Immune Sciences, Inc., Janux Therapeutics, Inc., Decibel Therapeutics, Inc., Adaptimmune Therapeutics PLC, Principia Biopharma Inc., PMV Pharmaceuticals, Inc., Prevail Therapeutics, Inc., Sierra Oncology, Inc., and Synthorx Inc. Dr. Thompson also currently serves on the board of directors of several private companies. Dr. Thompson co-founded Silverback Therapeutics, Inc. and Cleave Biosciences Inc. Dr. Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and Becton, Dickinson and Company. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds numerous patents and is a board-certified internist and oncologist. Dr. Thompson received a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School. - Peter Thompson，曾担任Corvus Pharmaceuticals， Inc.的成员。自2014年11月担任董事会成员，并共同创立了公司。Thompson博士是投资公司OrbiMed Advisors LLC的成员。Thompson博士目前担任ARS Pharmaceuticals， Inc.（原Silverback Therapeutics， Inc.）， Edgewise Therapeutics, Inc.和Sionna Therapeutics， Inc.以及几家私人公司的董事会成员。此前，Thompson博士担任Alpine Immune Sciences， Inc.、分贝治疗公司、Janux Therapeutics， Inc.、PMV Pharmaceuticals, Inc.和precpretherapeutics Inc.的董事会成员。Thompson博士此前还曾担任Trubion Pharmaceuticals， Inc.、Chiron Corporation和Becton， Dickinson and Company的执行领导职务。Thompson博士是华盛顿大学神经外科副教授。此外，Thompson博士拥有多项专利，是董事会认证的内科医生和肿瘤学家。他持有Brown大学的分子生物学和数学学士学位，以及Brown大学Medical School的医学博士学位。
- Peter Thompson,is a Partner at OrbiMed Advisors LLC, an investment firm focused on the healthcare sector, where he previously served as a Venture Partner since joining in September 2010. Dr. Thompson is also the Chairman of Terremoto Biosciences, Inc., a biotechnology company developing targeted therapeutics, since August 2024, where he previously served as President and Chief Executive Officer from August 2021 to August 2024. Dr. Thompson previously served as Chief Executive Officer and President of two private companies: Glia Biotherapeutics, Inc., a biopharmaceutical company targeting glia-mediated pathways from July 2018 to July 2023 and Terremoto Therapeutics Holdings, LLC, a drug discovery and development company from August 2021 to December 2022. Dr. Thompson currently serves on the boards of directors of several public companies, including Sionna Therapeutics, Inc. (since February 2022), Corvus Pharmaceuticals, Inc. (since November 2014), and ARS Pharmaceuticals Inc. (since April 2016). Dr. Thompson has previously served on the boards of directors of Alpine Immune Sciences, Inc., Janux Therapeutics, Inc., Decibel Therapeutics, Inc., Adaptimmune Therapeutics PLC, Principia Biopharma Inc., PMV Pharmaceuticals, Inc., Prevail Therapeutics, Inc., Sierra Oncology, Inc., and Synthorx Inc. Dr. Thompson also currently serves on the board of directors of several private companies. Dr. Thompson co-founded Silverback Therapeutics, Inc. and Cleave Biosciences Inc. Dr. Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and Becton, Dickinson and Company. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds numerous patents and is a board-certified internist and oncologist. Dr. Thompson received a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School.
- Christopher Peetz
-
Christopher Peetz自2018年4月以来一直担任我们的董事会成员。Peetz先生自2019年3月起担任MirumPharmaceuticals，Inc.总裁兼首席执行官，自2018年11月起担任总裁。自2017年5月以来，他一直担任Frazier梦百合Partners的常驻企业家。他曾于2017年5月至2019年12月担任Flashlight Therapeutics，Inc.的首席执行官，并于2014年5月至2016年12月担任TobiraTherapeutics，Inc.（一家上市生物技术公司，于2016年11月被Allergan plc收购）的首席财务官兼企业发展主管。加入Tobira Therapeutics公司之前，Peetz先生曾担任Jennerex Biotherapeutics公司（一家私营生物制药公司）的Vice President、财务与公司发展部。在加入Jennerex之前，Peetz先生曾在OnyxPharmaceuticals，Inc.（现为Amgen）担任多个职位，包括监督财务规划和分析、公司战略、产品生命周期管理和商业角色。在Onyx之前，Peetz先生在LaSalle Corporate Finance（ABN AMRO的一部分）提供并购咨询服务，并在Abgenix Inc.和Solazyme Inc.担任职位。Peetz先生在斯坦福商学院（Stanford Graduate School of Business）获得工商管理硕士学位，并在圣路易斯的华盛顿大学（Washington University）获得金融、国际商务与法语的B.S.B.A.。
Christopher Peetz,is Mirum Pharmaceuticals, Inc. co-founder and has served as Mirum Pharmaceuticals, Inc. President since December 2018 and as Mirum Pharmaceuticals, Inc. Chief Executive Officer since March 2019. Mr. Peetz has been an Entrepreneur-in-Residence at Frazier since May 2017. Prior to joining Mirum Pharmaceuticals, Inc. company, Mr. Peetz served as the Chief Executive Officer of Flashlight Therapeutics, Inc., a biotechnology company, from May 2017 to May 2019. From May 2014 to December 2016, Mr. Peetz served as Chief Financial Officer and head of corporate development at Tobira Therapeutics, Inc., a public biotechnology company acquired by Allergan plc, in November 2016. Prior to joining Tobira, Mr. Peetz served as Vice President, Finance and Corporate Development of Jennerex Biotherapeutics, Inc., a biopharmaceutical company, from April 2012 to March 2014. Prior to Jennerex, Mr. Peetz held various positions at Onyx Pharmaceuticals, Inc., including oversight of financial planning and analysis, corporate strategy, product lifecycle management and commercial roles. Prior to Onyx, Mr. Peetz provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. He currently serves on the board of directors of Alpine Immune Sciences, Inc., a public immunotherapy company. Mr. Peetz received an MBA from Stanford Graduate School of Business and a B.S.B.A. in Finance, International Business and French from Washington University in St. Louis. - Christopher Peetz自2018年4月以来一直担任我们的董事会成员。Peetz先生自2019年3月起担任MirumPharmaceuticals，Inc.总裁兼首席执行官，自2018年11月起担任总裁。自2017年5月以来，他一直担任Frazier梦百合Partners的常驻企业家。他曾于2017年5月至2019年12月担任Flashlight Therapeutics，Inc.的首席执行官，并于2014年5月至2016年12月担任TobiraTherapeutics，Inc.（一家上市生物技术公司，于2016年11月被Allergan plc收购）的首席财务官兼企业发展主管。加入Tobira Therapeutics公司之前，Peetz先生曾担任Jennerex Biotherapeutics公司（一家私营生物制药公司）的Vice President、财务与公司发展部。在加入Jennerex之前，Peetz先生曾在OnyxPharmaceuticals，Inc.（现为Amgen）担任多个职位，包括监督财务规划和分析、公司战略、产品生命周期管理和商业角色。在Onyx之前，Peetz先生在LaSalle Corporate Finance（ABN AMRO的一部分）提供并购咨询服务，并在Abgenix Inc.和Solazyme Inc.担任职位。Peetz先生在斯坦福商学院（Stanford Graduate School of Business）获得工商管理硕士学位，并在圣路易斯的华盛顿大学（Washington University）获得金融、国际商务与法语的B.S.B.A.。
- Christopher Peetz,is Mirum Pharmaceuticals, Inc. co-founder and has served as Mirum Pharmaceuticals, Inc. President since December 2018 and as Mirum Pharmaceuticals, Inc. Chief Executive Officer since March 2019. Mr. Peetz has been an Entrepreneur-in-Residence at Frazier since May 2017. Prior to joining Mirum Pharmaceuticals, Inc. company, Mr. Peetz served as the Chief Executive Officer of Flashlight Therapeutics, Inc., a biotechnology company, from May 2017 to May 2019. From May 2014 to December 2016, Mr. Peetz served as Chief Financial Officer and head of corporate development at Tobira Therapeutics, Inc., a public biotechnology company acquired by Allergan plc, in November 2016. Prior to joining Tobira, Mr. Peetz served as Vice President, Finance and Corporate Development of Jennerex Biotherapeutics, Inc., a biopharmaceutical company, from April 2012 to March 2014. Prior to Jennerex, Mr. Peetz held various positions at Onyx Pharmaceuticals, Inc., including oversight of financial planning and analysis, corporate strategy, product lifecycle management and commercial roles. Prior to Onyx, Mr. Peetz provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. He currently serves on the board of directors of Alpine Immune Sciences, Inc., a public immunotherapy company. Mr. Peetz received an MBA from Stanford Graduate School of Business and a B.S.B.A. in Finance, International Business and French from Washington University in St. Louis.
高管简历
中英对照 | 中文 | 英文- Stanford Peng
Stanford Peng自2019年4月以来一直担任我们的总裁兼研究与开发负责人，在此之前，他曾担任我们研究与开发的执行Vice President，并自Nivalis合并完成以来担任首席医疗官Private Alpine于2017年7月担任Private Alpine的首席医疗官（2016年9月至2017年2月），并于2017年2月至合并完成期间担任Private Alpine的研究与开发执行Vice President兼首席医疗官。在加入Private Alpine之前，彭博士曾于2015年至2016年担任StemcentRx的首席医疗官兼临床开发主管，为公司的临床和转化计划提供战略监督。此前，他曾担任Seattle Genetics公司的执行医疗董事，在那里他曾开发多种抗体药物结合物项目（2014年至2015年）。职业生涯早期，他曾领导Benaroya Research Institute的转化研究和自身免疫相关临床试验（从2009年到2014年），担任风湿病临床研究单位主管，也曾担任Roche公司的高级董事，负责临床研究和探索开发（从2005年到2008年）。2009年至2014年，彭博士还担任Virginia Mason Medical Center的会员医师。彭博士于2002年至2005年担任华盛顿大学医学院的助理教授。从2008年到2009年，鹏博士担任ARYxTherapeutics，Inc.的高级总监纳斯达克股票代码:ARYX。Peng博士在耶鲁大学医学院（Yale University School of Medicine）获得生物学硕士学位和博士学位，在斯坦福大学（Stanford University）获得音乐学士学位和生物科学学士学位。
Stanford Peng has served as Alpine Immune Sciences, Inc.'s president and head of research and development since April 2019 prior to which he served as Alpine Immune Sciences, Inc.'s executive vice president of research and development and chief medical officer since the completion of the merger of Nivalis and Private Alpine in July 2017 as Private Alpine's chief medical officer from September 2016 to February 2017 and as Private Alpine's executive vice president of research and development and chief medical officer from February 2017 until completion of the merger. Prior to joining Private Alpine, Dr. Peng was chief medical officer and head of clinical development at Stemcentrx, providing strategic oversight of the company's clinical and translational programs from 2015 to 2016. Previously, Dr. Peng was executive medical director at Seattle Genetics where he developed multiple programs for antibody-drug conjugates from 2014 to 2015. Earlier in his career, he directed translational research and auto-immune related clinical trials as head of the Rheumatology Clinical Research Unit at the Benaroya Research Institute from 2009 to 2014 and served as senior director, clinical research and exploratory development at Roche from 2005 to 2008. Between 2009 and 2014 Dr. Peng also served as member physician at Virginia Mason Medical Center. Dr. Peng served as an assistant professor at the Washington University School of Medicine from 2002 to 2005. From 2008 to 2009 Dr. Peng served as senior director at ARYx Therapeutics, Inc. Nasdaq: ARYX. Dr. Peng received an M.D. and Ph.D. in biology from the Yale University School of Medicine and a B.A. in music and B.S. in biological sciences from Stanford University.- Stanford Peng自2019年4月以来一直担任我们的总裁兼研究与开发负责人，在此之前，他曾担任我们研究与开发的执行Vice President，并自Nivalis合并完成以来担任首席医疗官Private Alpine于2017年7月担任Private Alpine的首席医疗官（2016年9月至2017年2月），并于2017年2月至合并完成期间担任Private Alpine的研究与开发执行Vice President兼首席医疗官。在加入Private Alpine之前，彭博士曾于2015年至2016年担任StemcentRx的首席医疗官兼临床开发主管，为公司的临床和转化计划提供战略监督。此前，他曾担任Seattle Genetics公司的执行医疗董事，在那里他曾开发多种抗体药物结合物项目（2014年至2015年）。职业生涯早期，他曾领导Benaroya Research Institute的转化研究和自身免疫相关临床试验（从2009年到2014年），担任风湿病临床研究单位主管，也曾担任Roche公司的高级董事，负责临床研究和探索开发（从2005年到2008年）。2009年至2014年，彭博士还担任Virginia Mason Medical Center的会员医师。彭博士于2002年至2005年担任华盛顿大学医学院的助理教授。从2008年到2009年，鹏博士担任ARYxTherapeutics，Inc.的高级总监纳斯达克股票代码:ARYX。Peng博士在耶鲁大学医学院（Yale University School of Medicine）获得生物学硕士学位和博士学位，在斯坦福大学（Stanford University）获得音乐学士学位和生物科学学士学位。
- Stanford Peng has served as Alpine Immune Sciences, Inc.'s president and head of research and development since April 2019 prior to which he served as Alpine Immune Sciences, Inc.'s executive vice president of research and development and chief medical officer since the completion of the merger of Nivalis and Private Alpine in July 2017 as Private Alpine's chief medical officer from September 2016 to February 2017 and as Private Alpine's executive vice president of research and development and chief medical officer from February 2017 until completion of the merger. Prior to joining Private Alpine, Dr. Peng was chief medical officer and head of clinical development at Stemcentrx, providing strategic oversight of the company's clinical and translational programs from 2015 to 2016. Previously, Dr. Peng was executive medical director at Seattle Genetics where he developed multiple programs for antibody-drug conjugates from 2014 to 2015. Earlier in his career, he directed translational research and auto-immune related clinical trials as head of the Rheumatology Clinical Research Unit at the Benaroya Research Institute from 2009 to 2014 and served as senior director, clinical research and exploratory development at Roche from 2005 to 2008. Between 2009 and 2014 Dr. Peng also served as member physician at Virginia Mason Medical Center. Dr. Peng served as an assistant professor at the Washington University School of Medicine from 2002 to 2005. From 2008 to 2009 Dr. Peng served as senior director at ARYx Therapeutics, Inc. Nasdaq: ARYX. Dr. Peng received an M.D. and Ph.D. in biology from the Yale University School of Medicine and a B.A. in music and B.S. in biological sciences from Stanford University.
- Mitchell H. Gold
自Nivalis Therapeutics，Inc.（我们称为Nivalis和Alpine Immune Sciences）合并完成以来，MitchellH.Gold一直担任我们的执行主席、首席执行官和董事会成员，Inc.（我们称为Private Alpine）于2017年7月合并之前，自2016年6月起担任Private Alpine的首席执行官，自2015年1月起担任Private Alpine的执行主席兼董事会成员。在共同创立Private Alpine之前，Gold博士于2012年至2014年担任Alpine Biosciences（一家私人持有的生物技术公司）的董事长兼创始人。从2001年到2012年，Gold博士在Dendreon Corporation（Valeant Pharmaceuticals International，Inc.通过资产购买协议收购）担任多个职位，包括总裁、首席执行官和董事会主席。在职业生涯早期，从2000年到2001年，Gold博士担任Data Critical的业务发展Vice President。从1995年到2000年，Gold博士担任Elixis Corporation的总裁兼首席执行官。Gold博士目前是Alpine BioVentures的管理合伙人。Gold博士持有Rush University Medical Center的Rush Medical College的医学博士学位，以及威斯康星大学（University of Wisconsin）的生物学学士学位。
Mitchell H. Gold has served as Alpine Immune Sciences, Inc.'s executive chairman, chief executive officer and a member of Alpine Immune Sciences, Inc.'s board of directors since the completion of the merger of Nivalis Therapeutics, Inc. which we refer to as Nivalis and Alpine Immune Sciences, Inc. (which we refer to as Private Alpine) in July 2017 and prior to the merger served as Private Alpine's chief executive officer since June 2016 and as Private Alpine's executive chairman and member of Private Alpine's board of directors since January 2015. Prior to co-founding Private Alpine, Dr. Gold was Chairman and Founder of Alpine Biosciences, a privately-held biotech company, from 2012 to 2014. From 2001 to 2012 Dr. Gold served in a variety of roles with Dendreon Corporation (which was acquired by Valeant Pharmaceuticals International, Inc. through an asset purchase agreement), including President, Chief Executive Officer, and Chairman of the board of directors. Earlier in his career, Dr. Gold served as Vice President of Business Development at Data Critical from 2000 to 2001. From 1995 to 2000 Dr. Gold was President and Chief Executive Officer of Elixis Corporation. Dr. Gold is currently a Managing Partner at Alpine BioVentures. Dr. Gold holds an M.D. from Rush Medical College of Rush University Medical Center and a B.S. in Biology from the University of Wisconsin.- 自Nivalis Therapeutics，Inc.（我们称为Nivalis和Alpine Immune Sciences）合并完成以来，MitchellH.Gold一直担任我们的执行主席、首席执行官和董事会成员，Inc.（我们称为Private Alpine）于2017年7月合并之前，自2016年6月起担任Private Alpine的首席执行官，自2015年1月起担任Private Alpine的执行主席兼董事会成员。在共同创立Private Alpine之前，Gold博士于2012年至2014年担任Alpine Biosciences（一家私人持有的生物技术公司）的董事长兼创始人。从2001年到2012年，Gold博士在Dendreon Corporation（Valeant Pharmaceuticals International，Inc.通过资产购买协议收购）担任多个职位，包括总裁、首席执行官和董事会主席。在职业生涯早期，从2000年到2001年，Gold博士担任Data Critical的业务发展Vice President。从1995年到2000年，Gold博士担任Elixis Corporation的总裁兼首席执行官。Gold博士目前是Alpine BioVentures的管理合伙人。Gold博士持有Rush University Medical Center的Rush Medical College的医学博士学位，以及威斯康星大学（University of Wisconsin）的生物学学士学位。
- Mitchell H. Gold has served as Alpine Immune Sciences, Inc.'s executive chairman, chief executive officer and a member of Alpine Immune Sciences, Inc.'s board of directors since the completion of the merger of Nivalis Therapeutics, Inc. which we refer to as Nivalis and Alpine Immune Sciences, Inc. (which we refer to as Private Alpine) in July 2017 and prior to the merger served as Private Alpine's chief executive officer since June 2016 and as Private Alpine's executive chairman and member of Private Alpine's board of directors since January 2015. Prior to co-founding Private Alpine, Dr. Gold was Chairman and Founder of Alpine Biosciences, a privately-held biotech company, from 2012 to 2014. From 2001 to 2012 Dr. Gold served in a variety of roles with Dendreon Corporation (which was acquired by Valeant Pharmaceuticals International, Inc. through an asset purchase agreement), including President, Chief Executive Officer, and Chairman of the board of directors. Earlier in his career, Dr. Gold served as Vice President of Business Development at Data Critical from 2000 to 2001. From 1995 to 2000 Dr. Gold was President and Chief Executive Officer of Elixis Corporation. Dr. Gold is currently a Managing Partner at Alpine BioVentures. Dr. Gold holds an M.D. from Rush Medical College of Rush University Medical Center and a B.S. in Biology from the University of Wisconsin.
- Paul Rickey
Paul Rickey， 2009年7月他加入Immune Design并担任财务和行政副总裁，秘书和财务主管。加入Immune Design之前，他担任各种职位，最后从2006年7月到2009年6月他担任Northstar Neuroscience（公开上市的医疗器械公司）的公司财务主管。此前从2004年到2006年，他担任 Mobliss Inc.，（无线软件公司）的会计经理。从2001年到2004年，他担任Ernst & Young LLP（国际专业服务公司）的员工。他获得he University of Washington的工商管理会计方向的学士学位和专业会计硕士学位。他目前在Northwest Association of Bioscience Financial Officers的董事会任职，他获得华盛顿州的注册会计师证书。他目前拥有其活跃证书。
Paul Rickey has served as Alpine Immune Sciences, Inc.'s senior vice president and chief financial officer since the completion of the merger of Nivalis and Private Alpine in July 2017 and prior to the merger served as Private Alpine's senior vice president and chief financial officer since April 2017. Mr. Rickey previously served as chief financial officer of Sound Pharmaceuticals, overseeing finance, accounting and human resources from March 2016 to March 2017. Before joining Sound Pharmaceuticals, Mr. Rickey was vice president of finance and administration of Immune Design Corp. from 2009 to May 2015 which was a publicly traded biotechnology company for a portion of his time there, where he helped complete the company's private offerings, initial public offering, and follow-on financing, and also oversaw the corporate development, accounting and human resource functions. Before joining Immune Design in 2009 Mr. Rickey was corporate controller of Northstar Neuroscience, a publicly-traded medical device company, where he managed the company's finance and accounting groups following Northstar's initial public offering. Prior to his role at Northstar Neuroscience, Mr. Rickey was the accounting manager for Mobliss, Inc., a mobile technology company that was sold to Index Corp., of Japan. Mr. Rickey started his finance career at Ernst & Young LLP. Mr. Rickey graduated from the University of Washington with a B.A. and Masters in Professional Accounting and is a certified public accountant, inactive.- Paul Rickey， 2009年7月他加入Immune Design并担任财务和行政副总裁，秘书和财务主管。加入Immune Design之前，他担任各种职位，最后从2006年7月到2009年6月他担任Northstar Neuroscience（公开上市的医疗器械公司）的公司财务主管。此前从2004年到2006年，他担任 Mobliss Inc.，（无线软件公司）的会计经理。从2001年到2004年，他担任Ernst & Young LLP（国际专业服务公司）的员工。他获得he University of Washington的工商管理会计方向的学士学位和专业会计硕士学位。他目前在Northwest Association of Bioscience Financial Officers的董事会任职，他获得华盛顿州的注册会计师证书。他目前拥有其活跃证书。
- Paul Rickey has served as Alpine Immune Sciences, Inc.'s senior vice president and chief financial officer since the completion of the merger of Nivalis and Private Alpine in July 2017 and prior to the merger served as Private Alpine's senior vice president and chief financial officer since April 2017. Mr. Rickey previously served as chief financial officer of Sound Pharmaceuticals, overseeing finance, accounting and human resources from March 2016 to March 2017. Before joining Sound Pharmaceuticals, Mr. Rickey was vice president of finance and administration of Immune Design Corp. from 2009 to May 2015 which was a publicly traded biotechnology company for a portion of his time there, where he helped complete the company's private offerings, initial public offering, and follow-on financing, and also oversaw the corporate development, accounting and human resource functions. Before joining Immune Design in 2009 Mr. Rickey was corporate controller of Northstar Neuroscience, a publicly-traded medical device company, where he managed the company's finance and accounting groups following Northstar's initial public offering. Prior to his role at Northstar Neuroscience, Mr. Rickey was the accounting manager for Mobliss, Inc., a mobile technology company that was sold to Index Corp., of Japan. Mr. Rickey started his finance career at Ernst & Young LLP. Mr. Rickey graduated from the University of Washington with a B.A. and Masters in Professional Accounting and is a certified public accountant, inactive.